IGF2R/M6PR Antibody (29): sc-136321

IGF-IIR Antibody (29) is a mouse monoclonal IgG1 kappa light chain antibody that detects IGF-IIR protein of mouse and rat origin by western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). IGF-IIR (29) antibody is available in both non-conjugated and various conjugated forms, including agarose and horseradish peroxidase (HRP). The insulin-like growth factor II receptor (IGF-IIR), also known as M6P/IGF2R, is a vital integral glycoprotein that plays a crucial role in cellular processes by binding glycoproteins through extracytoplasmic domains. This interaction is essential for mediating the activation of transforming growth factor beta 1 (TGFβ1), which acts as a growth inhibitor, as well as facilitating the degradation of insulin-like growth factor II (IGF-II) and the transport of lysosomal enzymes. IGF-IIR forms oligomeric complexes to enhance affinity for lysosomal enzymes, promoting efficient cellular function. Unlike IGF-IR, IGF-IIR does not amplify IGF-I or IGF-II signaling pathways, which are known for mitogenic and cell survival effects, positioning anti-IGF-IIR antibody (29) as a significant tumor suppressor. IGF-IIR gene is located on chromosome 6q26, a region frequently associated with mutations or deletions in various human cancers, underscoring IGF-IIR′s importance in cancer biology and potential therapeutic interventions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IGF2R/M6PR Antibody (29) References:

1. Insulin-like growth factors in human breast cancer.  |  Ellis, MJ., et al. 1998. Breast Cancer Res Treat. 52: 175-84. PMID: 10066081
2. Type-2 IGF receptor: a multi-ligand binding protein.  |  Braulke, T. 1999. Horm Metab Res. 31: 242-6. PMID: 10226808
3. M6P/IGF2R is mutated in squamous cell carcinoma of the lung.  |  Kong, FM., et al. 2000. Oncogene. 19: 1572-8. PMID: 10734317
4. Mechanisms for high affinity mannose 6-phosphate ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor.  |  Byrd, JC. and MacDonald, RG. 2000. J Biol Chem. 275: 18638-46. PMID: 10764735
5. Dimerization of the insulin-like growth factor II/mannose 6-phosphate receptor.  |  Byrd, JC., et al. 2000. J Biol Chem. 275: 18647-56. PMID: 10764761
6. Invasive properties of murine squamous carcinoma cells: secretion of matrix-degrading cathepsins is attributable to a deficiency in the mannose 6-phosphate/insulin-like growth factor II receptor.  |  Lorenzo, K., et al. 2000. Cancer Res. 60: 4070-6. PMID: 10945612
7. Mutation analysis of the gene encoding the human mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) in human cell lines resistant to growth inhibition by transforming growth factor beta(1) (TGF-beta(1)).  |  Gemma, A., et al. 2000. Lung Cancer. 30: 91-8. PMID: 11086202
8. The N terminus of mannose 6-phosphate/insulin-like growth factor 2 receptor in regulation of fibrinolysis and cell migration.  |  Leksa, V., et al. 2002. J Biol Chem. 277: 40575-82. PMID: 12189157
9. Doxorubicin attenuates CHIP-guarded HSF1 nuclear translocation and protein stability to trigger IGF-IIR-dependent cardiomyocyte death.  |  Huang, CY., et al. 2016. Cell Death Dis. 7: e2455. PMID: 27809308
10. p53-mediated miR-18 repression activates HSF2 for IGF-IIR-dependent myocyte hypertrophy in hypertension-induced heart failure.  |  Huang, CY., et al. 2017. Cell Death Dis. 8: e2990. PMID: 28796250
11. Inhibition of ERK-Drp1 signaling and mitochondria fragmentation alleviates IGF-IIR-induced mitochondria dysfunction during heart failure.  |  Huang, CY., et al. 2018. J Mol Cell Cardiol. 122: 58-68. PMID: 30098987
12. Artemisia argyi mitigates doxorubicin-induced cardiotoxicity by inhibiting mitochondrial dysfunction through the IGF-IIR/Drp1/GATA4 signaling pathway.  |  Chen, JK., et al. 2024. Biotechnol Appl Biochem.. PMID: 39375847

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-IGF2R/M6PR Antibody (29) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-IGF2R/M6PR Antibody (29) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

IGF2R/M6PR Antibody (29) Specifications

Alternate Product Name: IGF2R

Product Clone Name: 29

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 245-441

Epitope Target: IGF-IIR

Epitope Species: rat

Product Reactivity/Detection: IGF-IIR

Species Reactivity/Detection: mouse, rat

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for IGF2R/M6PR Antibody (29): AC: Agarose, HRP: Horseradish Peroxidase